CD274 and urothelial carcinoma: In contrast, the Checkmate-032 trial found that urothelial carcinoma patients with minimal PD-L1 expression (<1%) achieved a higher objective remission rate [15], while the Impower-133 trial reported no association between PD-L1 expression and efficacy in small cell lung cancer [16].